Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

被引:60
作者
Gaedigk, A
Bhathena, A
Ndjountché, L
Pearce, RE
Abdel-Rahman, SM
Alander, SW
Bradford, LD
Leeder, JS
机构
[1] Childrens Mercy Hosp & Clin, Div Clin Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA
[2] Morehouse Sch Med, Atlanta, GA 30310 USA
关键词
CYP2D6; SNPs; haplotype; dextromethorphan; African American;
D O I
10.1038/sj.tpj.6500305
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cytochrome P4502D6 (CYP2D6) genotyping reliably predicts poor metabolizer phenotype in Caucasians, but is less accurate in African Americans. To evaluate discordance we have observed in phenotype to genotype correlation studies, select African American subjects were chosen for complete resequencing of the CYP2D6 gene including 4.2 kb of the CYP2D7-2D6 intergenic region. Comparisons were made to a CYP2D6*1 reference sequence revealing novel SNPs in the upstream, coding and intervening sequences. These sequence variations, defining four functional alleles (CYP2D6* 41B, * 45A and B and * 46), were characterized for their ability to influence splice site strength, transcription level or catalytic protein activity. Furthermore, their frequency was determined in a population of 251 African Americans. A - 692(TGTG) deletion ( CYP2D6* 45B) did not significantly decrease gene expression, nor could any other upstream SNP explain a genotype-discordant case. CYP2D6* 45 and * 46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype.
引用
收藏
页码:173 / 182
页数:10
相关论文
共 41 条
[21]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391
[22]   CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles [J].
Leathart, JBS ;
London, SJ ;
Steward, A ;
Adams, JD ;
Idle, JR ;
Daly, AK .
PHARMACOGENETICS, 1998, 8 (06) :529-541
[23]   EVIDENCE FOR A DISSOCIATION IN THE CONTROL OF SPARTEINE, DEBRISOQUINE AND METOPROLOL METABOLISM IN NIGERIANS [J].
LENNARD, MS ;
IYUN, AO ;
JACKSON, PR ;
TUCKER, GT ;
WOODS, HF .
PHARMACOGENETICS, 1992, 2 (02) :89-92
[24]   Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine [J].
Marcucci, KA ;
Pearce, RE ;
Crespi, C ;
Steimel, DT ;
Leeder, JS ;
Gaedigk, A .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (05) :595-601
[25]   Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 [J].
Masimirembwa, C ;
Hasler, J ;
Bertilssons, L ;
Johansson, I ;
Ekberg, O ;
IngelmanSundberg, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (02) :117-122
[26]   A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects [J].
Raimundo, S ;
Toscano, C ;
Klein, K ;
Fischer, J ;
Griese, EU ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) :128-138
[27]   Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6 [J].
Raimundo, S ;
Fischer, R ;
Eichelbaum, M ;
Griese, EU ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2000, 10 (07) :577-581
[28]   Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations [J].
Rogan, PK ;
Svojanovsky, S ;
Leeder, JS .
PHARMACOGENETICS, 2003, 13 (04) :207-218
[29]  
Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO
[30]  
2-O